The authors of a Global Ecology and Biogeography study originally published in November 2009 and retracted last week are appealing the decision with the Committee on Publication Ethics (COPE), Retraction Watch has learned. Continue reading Authors plan to appeal Global Ecology and Biogeography retraction
Two weeks ago, we covered the retraction of a PNAS paper on a potential breast cancer treatment, one that would make tumors that didn’t respond to tamoxifen respond to the drug. We learned earlier this week from a Retraction Watch commenter that Wnt Research, a company based on the breast cancer finding and other work, was about to go public.
In fact, their initial public offering (IPO) happened today, and you can follow the price of their stock — listed on the Stockholm Stock Exchange as WNT — here. But what we learned when we looked into the IPO was that it was originally scheduled for late November, and was delayed because of the retraction.
Tommy Andersson, one of the researchers on the now-retracted paper and Wnt Research’s chief scientific officer, told Retraction Watch that the company had initially planned on going public on November 26. They had written a memorandum describing the company’s work to date, and its plans, and the public was given a chance to invest before shares hit the Stockholm exchange. That memorandum included a mention of the PNAS paper, as follows (translated from Swedish): Continue reading Wnt Research: How a retraction delayed an IPO, shrunk investment — but should build public trust
On October 20, the Journal of the American Chemical Society retracted a 2009 paper. The retraction notice for “Single Gold Nanoparticles Counter: An Ultrasensitive Detection Platform for One-Step Homogeneous Immunoassays and DNA Hybridization Assays” was somewhat opaque:
This article is being retracted due to inaccurate DNA hybridization detection results caused by application of an incorrect data processing method. The authors regret any confusion that may have been created by the paper’s publication.
We contacted the paper’s lead author, Jicun Ren, of the College of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiaotong University, to ask for more detail. He responded: Continue reading Journal of the American Chemical Society retracts gold nanoparticle paper
C. P. Snow famously bemoaned the gulf between science and the humanities. The following retraction might be the sort of thing that would have given the physicist-cum-author fits for its estrangement from the English language.
Writing in the latest issue of Applied Physics Letters, a team from
China Singapore and MIT appear to be confessing a case of self-plagiarism in their 2005 paper, “Growth of single crystal ZnO nanorods on GaN using an aqueous solution method: (we added a link to the earlier paper)” Continue reading Obfuscation watch: Self-plagiarism (we think) leads to retraction of nanorod paper in Applied Physics Letters
As we’ve previously reported, German anesthesiologist Joachim Boldt has been under investigation for apparent misdeeds — including lack of proper informed consent and possible data fabrication — that led to the retraction earlier this year of an article in Anesthesia & Analgesia. We’ve just learned that Boldt also has drawn scrutiny from German prosecutors for his role in a clinical trial earlier in the decade that led to the death of one patient and the near-death of another.
According to an article in the Weinheimer Nachrichten, that incident occurred when Boldt was at the University Hospital Giessen. Officials there told us there was an investigation into the matter but declined to comment further.
Here’s Google’s translation of the Weinheimer Nachrichten piece: Continue reading Boldt under investigation for drug trial death
Two cases in point: We recently learned that the International Journal of Surgery, an Elsevier title, had withdrawn two papers from the CONSORT group — an acronym for Consolidated Standards of Reporting Trials — an international team of scientists who have been working on ways to improve the reporting of studies.
In 2008, they published a paper titled “Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments” in the Annals of Internal Medicine. They followed up in March 2010 with the publication of “CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials.”
As they wrote in the statement: Continue reading Penalties for early withdrawal: irked CONSORT Group authors
Earlier this week, we asked what is likely to happen to papers published by William Hamman, the United pilot who claimed — falsely — to also be a cardiologist. Read more about the episode here.
One of the journals in which Hamman published, the American Journal of Medical Quality, will “amend the paper to correct” Hamman’s credentials — or lack thereof, a journal staffer told us today. The journal hasn’t dealt with this sort of thing before, so is checking with the publisher before making the change. They “plan to get it done as quickly as they can do it.”
We haven’t seen this sort of thing either. Continue reading Journal will remove fake cardiologist William Hamman’s credentials, but paper will remain in print
It’s a mind-boggling story: A United Airlines pilot claims to be a cardiologist and was eagerly sought after for medical conferences at which he taught doctors teamwork. He shared millions in grants, according to the Associated Press. But as the AP reports, William Hamman wasn’t a cardiologist at all, having never even finished medical school.
Hamman’s career seems to be collapsing, now that he resigned from his post as a researcher and educator at Royal Oak, Michigan’s William Beaumont Hospital once the hospital found out he had misled them. (Just last year, Beaumont touted a $150,000 grant Hamman nabbed with a colleague, Marc Abramson at Improbable Research notes.) United has also grounded him.
The storyline is reminiscent of 2002’s Catch Me If You Can, in which Frank Abagnale Jr. (played by Leonardo DiCaprio) forges millions of dollars’ worth of checks around the world, in the process impersonating a Pan Am pilot and a doctor. In Hamman’s case, there are apparently no questions over whether his pilot credentials are legit, according to the AP.
Our interest at Retraction Watch is what happens to the papers Hamman has published over the years. There are at least six, including two published this year. The AP reported that Continue reading Catch Me If You Can: What happens to fake cardiologist William Hamman’s published papers?
There’s a retraction in the issue of Neurology published this week. In a nutshell, a group of researchers had reported earlier this year that they had identified a genetic mutation potentially responsible for a rare neurological disorder called the filamin myopathy. But when another group tried to replicate those results, they found that the original tests were probably contaminated by a “pseudogene.”
In a letter from the second group:
Kono et al reported the effects of a novel c.8107del mutation in the filamin C gene (FLNC). We reviewed their results and concluded that the reported mutation was mistaken identity.
In a response, the authors thank the group and conclude: Continue reading A retraction in Neurology highlights an unusual practice
We have an update on the case of Olav and Axel Gressner, a father-son (or, in this case, son-father) pair of German liver researchers caught up in a fraud investigation. The inquiry focused on Olav, who left the University of Aachen under a cloud of suspicion. A 2008 research letter on which he was a co-author (his father was senior author) was retracted earlier this year by the Journal of Hepatology.
The journal’s position in the retraction notice, published online in June and in print in September, bears repeating here. The authors: Continue reading Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”